Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder

NCT05549258 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05549258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05549258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Recruiting
Start date
July 3, 2023
Completion date
April 13, 2027
Enrollment
15 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

neuromyelitis optica spectrum disorder